Takeda and Ovid Report Results of Soticlestat (TAK-935/OV935) in P-II ELEKTRA Study for Dravet Syndrome or Lennox-Gastaut Syndrome


  • The P-II ELEKTRA study involves assessing of soticlestat vs PBO in pediatric patients, aged 2-17 yrs., with highly refractory epileptic seizures associated with DS (convulsive seizures) or LGS (drop seizures)
  • Results: meeting its 1EPs i.e. reduction in DS & LGS (27.8% vs 3.1% & 29.8% vs 0.0%) during the 12-wks. maintenance period & 20-wks. treatment period (titration plus maintenance) respectively. In DS cohort, reduction in convulsive seizure (33.8% vs 7.0%) during the full 20-week treatment period, following which companies are planning to initiate P-III program
  • In the LGS cohort, reduction in drop seizure frequency (20.6% vs 6.0%) during the full 20-week treatment period of the study. Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H)

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Northcott